This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

XOMA 629

XOMA Corporation

Drug Names(s): XMP.629

Description: XOMA 629 is a topical anti-bacterial formulation of a BPI-derived peptide (XMP.629) under development as a possible treatment for acne. XMP.629 is a novel synthetic peptide compound derived from bactericidal/permeability-increasing protein (BPI) -- a human host-defense protein that is part of the body's early lines of defense against invading microorganisms.

XOMA 629 News

Pink Sheet Xoma Halts Development Of Acne Therapy XMP.629, Will Evaluate BPI Program

Pink Sheet Xoma Halts Acne Therapy XMP.629 Development, Will Evaluate BPI Program

Scrip Xoma slashes manufacturing jobs

Pink Sheet Xoma’s New Business Strategy Emphasizes Proprietary Pipeline

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug